• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Anticholinergic-Associated Cognitive Impairment in Schizophrenia
RESEARCH UPDATE

Anticholinergic-Associated Cognitive Impairment in Schizophrenia

April 5, 2022
Brian Miller, MD, PhD, MPH.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Joshi YB et al, Am J Psychiatry 2021;178(9):838–847

STUDY TYPE: Cross-sectional study


Schizophrenia is associated with impaired cognition. Medications with anticholinergic properties, including antipsychotics, benztropine (Cogentin), and antidepressants, can worsen this problem and may confer increased risk of dementia. What we don’t know is the size of this impact on cognition, which this study aimed to ­characterize.

Researchers examined the magnitude and sources of medications with anticholinergic properties in schizophrenia, as well as their links to global cognition and cognitive subdomains. They conducted a cross-sectional study of 1,120 adult outpatients under age 65 with schizophrenia or schizoaffective disorder who participated in the larger Consortium on the Genetics of Schizophrenia-2 study. Most subjects were young (mean age 24 years), 69% were male, 43% were White, and 40% were Black. Patients had assessments of psychopathology, anticholinergic burden (using the Anticholinergic Cognitive Burden [ACB] scale), and cognition (using the Penn Computerized Neurocognitive Battery). The ACB is a validated expert rating scale that assigns dose-independent, categorical ratings to medications based on anticholinergic properties (with 1 = low/minimal, 2 = moderate, and 3 = strong/definite).

Most of the total anticholinergic burden was attributable to antipsychotics, followed by “traditional” anticholinergics (eg, benztropine, diphenhydramine, hydroxyzine, and trihexyphenidyl), antidepressants, mood stabilizers, and benzodiazepines (see also www.acbcalc.com). Most patients (90%) were taking a second-generation antipsychotic, 18% were taking two antipsychotics, and 20% were taking benztropine or a similar medication.

Greater anticholinergic burden was associated with significantly worse cognition scores, after controlling for potential confounding factors including dose and number of antipsychotics, psychotic symptom severity, illness duration, number of hospitalizations, and smoking. The global cognition of patients with high or very high anticholinergic burden was approximately 0.5 standard deviations worse compared to patients with no anticholinergic burden. This translates to greater cognitive impairment in patients with high anticholinergic burden, a finding that is of potential clinical significance.

Limitations of this study included the cross-sectional design, which precludes any causal inferences, and the exclusion of patients with significant medical conditions (leading to a likely underestimation of the impact of anticholinergic burden). Also, the ACB scale does not account for dose, previous medication exposures, or the effects of medication adherence.

CARLAT TAKE
Anticholinergic medications may impair cognition in schizophrenia, and that burden is raised by high doses of antipsychotics and excessive use of benztropine. Antipsychotics with a lower anticholinergic burden include brexpiprazole, lumateperone, lurasidone, ziprasidone, and the first-generation thiothixene.
General Psychiatry Research Update
KEYWORDS cognition negative-symptoms-of-schizophrenia schizophrenia side-effects
    Brian Miller, MD, PhD, MPH.

    Aripiprazole-Related Psychotic Exacerbations

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Thyroid Augmentation in Bipolar Disorder
    Prior Authorizations for Psychiatric Medications: A Primer for Frustrated Clinicians
    Anticholinergic-Associated Cognitive Impairment in Schizophrenia
    Structural Brain Changes After ECT for Depression
    Antidepressants: When Dosage Matters
    CME Post-Test - Thyroid and Mental Illness, TCPR, April 2022
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.